Flurazepam

Flurazepam

SCHEMBL29793

CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Flurazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 known ✓ P14867 4/20 0.49
GABRA5 known ✓ P31644 4/20 0.49
GABRA3 known ✓ P34903 4/20 0.49
GABRA2 known ✓ P47869 4/20 0.49
GABRB2 known ✓ P47870 4/20 0.49
GABRG2 known ✓ P18507 3/20 0.49
GABRB3 known ✓ P28472 3/20 0.49
GABRP known ✓ O00591 2/20 0.49
GABRD known ✓ O14764 2/20 0.49
GABRB1 known ✓ P18505 2/20 0.49
GABRA4 known ✓ P48169 2/20 0.49
GABRE known ✓ P78334 2/20 0.49
GABRA6 known ✓ Q16445 2/20 0.49
GABRG1 known ✓ Q8N1C3 2/20 0.49
GABRG3 known ✓ Q99928 2/20 0.49
GABRQ known ✓ Q9UN88 2/20 0.49
OPRK1 P41145 5/20 1.00
DRD3 P35462 2/20 1.00
KCNH2 Q12809 2/20 1.00
GHSR Q92847 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flurazepam SCHEMBL29565153 1.00 OPRK1 (1.00) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL10587083 1.00 OPRK1 (1.00) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL29368156 0.99 OPRK1 (0.98) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL29794 0.99 OPRK1 (0.98) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL30690402 0.99 OPRK1 (0.98) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL18396062 0.99 OPRK1 (0.98) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL5499515 0.99 OPRK1 (0.98) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL29792 0.99 OPRK1 (0.98) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL29378257 0.99 OPRK1 (0.98) OPRK1DRD3KCNH2GHSRHTR1A
Flurazepam SCHEMBL1650117 0.98 OPRK1 (0.96) OPRK1DRD3KCNH2GHSRHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 18650 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
US-12624036-B2 Method of treating post-traumatic stress disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
US-12624037-B2 Method of treating agitation, aggressive behavior, and impulse control disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
WO-2026090360-A1 FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC. (US) 2026-04-30 WO claimed
US-20260115192-A1 PHARMACEUTICAL COMPOSITIONS SHENZHEN PHARMACIN CO LTD (CN) 2026-04-30 US claimed
US-20260115161-A1 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN LAMINAR PHARMACEUTICALS S A (ES) 2026-04-30 US claimed
US-20260108529-A1 FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC (US) 2026-04-23 US claimed
US-12594388-B2 Device to deliver a predetermined amount of a substance to a natural orifice of the body APTARGROUP, INC. (US) 2026-04-07 US claimed
US-20260076953-A1 METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2026-03-19 US claimed
EP-3507371-B1 COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM UNIV RUTGERS (US) 2026-01-28 EP claimed
EP-0106335-A2 Pharmaceutical composition and a method for enhancing the absorption of a pharmaceutically active compound Tanabe Seiyaku Co., Ltd. (JP) 1984-04-25 EP claimed
EP-0098113-A1 A combination of beta-adrenoceptor antagonists and anxiolytic agents AYERST, MCKENNA AND HARRISON INC. (CA) 1984-01-11 EP claimed
WO-1983003968-A1 BRAIN-SPECIFIC DRUG DELIVERY UNIVERSITY OF FLORIDA (US) 1983-11-24 WO claimed
US-4316897-A TRANQUILIZERS HOFFMANN-LA ROCHE INC. (US) 1982-02-23 US claimed
EP-0025546-A2 Therapeutical use of tranquillizing benzodiazepine derivatives and mixtures containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-03-25 EP claimed
EP-0022771-A4 RADIO RECEPTOR ASSAY FOR BENZODIAZEPINES IN PLASMA AND OTHER BIOLOGICAL SPECIMENS. US HEALTH (US) 1981-02-04 EP claimed
EP-0022771-A1 RADIO RECEPTOR ASSAY FOR BENZODIAZEPINES IN PLASMA AND OTHER BIOLOGICAL SPECIMENS THE UNITED STATES OF AMERICA, represented by DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1981-01-28 EP claimed
WO-1980000750-A1 RADIO RECEPTOR ASSAY FOR BENZODIZAPINES IN PLASMA AND OTHER BIOLOGICAL SPECIMENS US COMMERCE (US) 1980-04-17 WO claimed
US-4028467-A Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process BERGER FRANK M 1977-06-07 US claimed
US-4028466-A Analgesic compositions comprising dextro-propoxyphene and benzodiazepine and process BERGER FRANK M 1977-06-07 US claimed